Search

everythinglearnresearchcommunity

for

Search:↓

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

JAK inhibitors offer new hope for treating severe alopecia areata.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.

Ruxolitinib can cause a delayed skin reaction on the nose.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Blocking mTORC1 reduces skin tumor growth in mice.

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

QLT0267 stops hair follicle cell growth and movement.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Finasteride helps treat hair loss and prostate enlargement by blocking a specific enzyme.

Nilotinib can cause keratosis pilaris, a skin condition.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.